Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Frequently asked questions
What sector does Mind Medicine (MindMed) Inc (MNMD) operate in?
Mind Medicine (MindMed) Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Mind Medicine (MindMed) Inc (MNMD) current stock price?
As of the latest data, Mind Medicine (MindMed) Inc stock price is $15.02, with a previous close of $14.87. Mind Medicine (MindMed) Inc gained $0.15 in the last trading session, representing a 1.01% increase.
What is Mind Medicine (MindMed) Inc (MNMD) current market capitalization?
Mind Medicine (MindMed) Inc market cap is approximately 1.46 billion.
What is Mind Medicine (MindMed) Inc (MNMD) Earnings Per Share (EPS)?
The trailing EPS is -$1.98, and the forward EPS is -$1.77.
Does Mind Medicine (MindMed) Inc (MNMD) pay dividends?
No. Mind Medicine (MindMed) Inc does not pay a dividend.
What is Mind Medicine (MindMed) Inc (MNMD) beta (volatility) score?
Mind Medicine (MindMed) Inc has a beta of 2.621, indicating very high volatility compared to the market.